---
title: "BCRX.US (BCRX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BCRX.US/news.md"
symbol: "BCRX.US"
name: "BCRX.US"
parent: "https://longbridge.com/en/quote/BCRX.US.md"
datetime: "2026-05-20T18:12:20.733Z"
locales:
  - [en](https://longbridge.com/en/quote/BCRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BCRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BCRX.US/news.md)
---

# BCRX.US (BCRX.US) — Related News

### [06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight](https://longbridge.com/en/news/286895360.md)
*2026-05-19T10:32:19.000Z*
> The Netherton syndrome market is projected to grow from 2026 to 2036, driven by new therapies like QRX003, BCX17725, and

### [BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://longbridge.com/en/news/285817937.md)
*2026-05-09T16:26:00.000Z*
> BioCryst Pharmaceuticals, Inc. unveiled that the compensation committee of their board of directors provided six newly r

### [These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings](https://longbridge.com/en/news/285595224.md)
*2026-05-07T17:46:12.000Z*
> BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, with earnings of 14 cents per share and sales of $156.413 mil

### [BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target](https://longbridge.com/en/news/285424618.md)
*2026-05-06T19:17:56.000Z*
> TD Cowen analyst Stacy Ku has reiterated a Buy rating on BioCryst (BCRX) stock, citing the strength of the Orladeyo fran

### [BioCryst Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 156.41 M](https://longbridge.com/en/news/285363741.md)
*2026-05-06T11:10:45.000Z*